Copay help by condition · Cancer and blood cancer · read 2026-11-08
Prostate Cancer: which charitable copay funds are open
All 4 funds we hold for Prostate Cancer are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Prostate Cancer
- Closed or at capacityProstate Cancer
CancerCare ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed). Source page
- Closed or at capacityProstate Cancer - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Closed. Source page
- Closed or at capacityProstate cancer
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $4,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
- Closed or at capacityProstate cancer health equity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $4,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Prostate Cancer
8 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 6 have a program (in our assistance finder or on the program's own page) and 1 has a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Erleada Apalutamide Every route for this drug | ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients ... Label on openFDA, read 2026-11-10 | J&J Patient Assistance Foundation (JJPAF) | selected by CMS for 2028; price not yet published |
| Xtandi Enzalutamide Every route for this drug | ... castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for ... Label on openFDA, read 2026-11-10 | Astellas Pharma Support Solutions (program page) Pfizer RxPathways Limited | $7,004.00 for a 30-day supply, effective 2027-01-01 |
| Truqap Capivasertib Every route for this drug | PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) ... Label on openFDA, read 2026-11-10 | AZ&Me Prescription Savings Program Limited | not in the CMS negotiated-price file |
| Nubeqa Darolutamide Every route for this drug | ... non-metastatic castration-resistant prostate cancer (nmCRPC). Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Lupron Depot Leuprolide Acetate Every route for this drug | VABRINTY is indicated for the treatment of advanced prostate cancer. Label on openFDA, read 2026-11-10 | myAbbVie Assist | not in the CMS negotiated-price file |
| Lynparza Olaparib Every route for this drug | Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant ... Label on openFDA, read 2026-11-10 | Cancer Drug Assistance (Multiple Programs) AZ&Me Prescription Savings Program Limited | not in the CMS negotiated-price file |
| Prolia Denosumab | Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate ... Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Orgovyx Relugolix | ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Funds for costs around Prostate Cancer
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: prostate-cancer.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Prostate Cancer?
As read on 2026-11-08, none of the 4 funds we hold for Prostate Cancer say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Prostate Cancer?
CancerCare, HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.